Content about Acquisition

February 18, 2014

Novartis on Monday announced that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals, a Cambridge, Mass.-based, privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer.

BASEL, Switzerland — Novartis on Monday announced that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals, a Cambridge, Mass.-based, privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer.

February 12, 2014

Mallinckrodt and Cadence Pharmaceuticals on Tuesday announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals for $14.00 per share in cash.

DUBLIN — Mallinckrodt and Cadence Pharmaceuticals on Tuesday announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals for $14.00 per share in cash or approximately $1.3 billion on a fully diluted basis, which represents a 32% premium to the trailing 30-trading-day volume weighted average price of $10.62 per share for Cadence Pharmaceuticals.

February 12, 2014

Private equity firm Yellow Wood Partners announced on Wednesday that its portfolio company Parfums de Coeur, a provider of mass-market fragrances and supplier of specialty bath products in the United States, has acquired Dr. Teal’s Therapeutic Solutions from health and beauty company Advanced Beauty.

BOSTON — Private equity firm Yellow Wood Partners announced on Wednesday that its portfolio company Parfums de Coeur, a provider of mass-market fragrances and supplier of specialty bath products in the United States, has acquired Dr. Teal’s Therapeutic Solutions from health and beauty company Advanced Beauty.

Terms of the deal were not disclosed.

February 6, 2014

Anheuser-Busch announced that it agreed to purchase Blue Point Brewing Co., a craft brewery. The purchase will bring additional resources to Blue Point's operations, allowing it to better meet consumer demand for its brands.

ST. LOUIS and LONG ISLAND, N.Y. — Anheuser-Busch announced that it agreed to purchase Blue Point Brewing Co., a craft brewery. The purchase will bring additional resources to Blue Point's operations, allowing it to better meet consumer demand for its brands. Terms of the agreement were not disclosed.

February 6, 2014

Coca-Cola and Green Mountain Coffee Roasters have signed a 10-year agreement to work together on the development and introduction of Coca-Cola’s global brand portfolio for use in GMCR's upcoming Keurig Cold at-home beverage system.

ATLANTA and WATERBURY, Vt. — Coca-Cola and Green Mountain Coffee Roasters have signed a 10-year agreement to work together on the development and introduction of Coca-Cola’s global brand portfolio for use in GMCR's upcoming Keurig Cold at-home beverage system.

Under the agreement, the companies will cooperate to bring the Keurig Cold beverage system to consumers around the world. The companies also entered into a Common Stock Purchase Agreement; Coca-Cola will purchase a 10% minority equity position in GMCR.

January 31, 2014

GoJo Industries on Friday announced the acquisition of Laboratoires Prodene Klint. Based in France, Prodene Klint specializes in professional hygiene, cosmetics and disinfectant products.

AKRON, Ohio — GoJo Industries on Friday announced the acquisition of Laboratoires Prodene Klint. Based in France, Prodene Klint specializes in professional hygiene, cosmetics and disinfectant products.  

Terms of the transaction were not disclosed. 

January 21, 2014

Actavis Pharma recently announced that it intends to enter into an agreement for Aurobindo Pharma to acquire Actavis' generics commercial operations in seven markets in Western Europe.

DUBLIN — Actavis Pharma recently announced that it intends to enter into an agreement for Aurobindo Pharma to acquire Actavis' generics commercial operations in seven markets in Western Europe. The transaction is conditional on certain antitrust approvals and completion of employee consultation processes. 

January 21, 2014

Par Pharmaceuticals Cos. on Tuesday announced that it entered into an agreement to acquire JHP Group Holdings, parent company of JHP Pharmaceuticals.

WOODCLIFF LAKE, N.J. — Par Pharmaceuticals Cos. on Tuesday announced that it entered into an agreement to acquire JHP Group Holdings, parent company of JHP Pharmaceuticals.

JHP is a specialty pharmaceutical company that develops, manufactures and markets branded and generic sterile injectable products. It currently markets a portfolio of 14 specialty injectable products, such as Aplisol and Adrenalin.

January 14, 2014

Three drug makers are looking into buying Pfizer's branded-generics drug business, according to published reports.

NEW YORK — Three drug makers are looking into buying Pfizer's branded-generics drug business, according to published reports.

Reuters reported that Actavis, Valeant Pharmaceuticals International and Mylan had expressed interest in buying Pfizer's business segment focused on generic drugs. However, Reuters reported that Pfizer was not yet ready to make a deal and was in the process of a potential separation of the generics unit.

January 6, 2014

Global beauty company Coty has entered into an agreement to acquire Lena White, the largest international distributor of OPI, which is one of Coty's power brands.

NEW YORK — Global beauty company Coty has entered into an agreement to acquire Lena White, the largest international distributor of OPI, which is one of Coty's power brands.

For the past 30 years, Lena White has served as OPI's distributor in the U.K. for the professional and retail beauty channels.

Through this purchase, Coty will directly lead the development of the OPI brand in the U.K., its second-largest market, providing the necessary resources to accelerate development in both retail and professional channels.

December 30, 2013

Back to Nature Foods Company on Monday announced that it has acquired SnackWell's, a cookie and snack business, from Mondelez Global.

GREENWICH, Conn. — Back to Nature Foods Company on Monday announced that it has acquired SnackWell's, a cookie and snack business, from Mondelez Global. The terms and conditions of the deal were not disclosed.

December 27, 2013

Drug maker Shire is extending the deadline for its offer to buy Exton, Pa.-based ViroPharma for $4.2 billion, Shire said Friday.

DUBLIN — Drug maker Shire is extending the deadline for its offer to buy Exton, Pa.-based ViroPharma for $4.2 billion, Shire said Friday.

The company said it had extended the expiration date of its tender offer for ViroPharma until Jan. 9. The offer had previously been planned to expire on Thursday. Shire announced the $50-per-share offer last month.

December 23, 2013

As Seen On TV, a multichannel distributor of products in such areas as kitchen, outdoor, electronics and clothing, announced that it signed a memorandum of understanding to acquire Infusion Brands International, the marketer behind the renowned "Dual" brand and the strategic partner of Ronco Holdings.

CLEARWATER, Fla.— As Seen On TV — a multichannel distributor of products in such areas as kitchen, outdoor, electronics and clothing — on Monday announced that it signed a memorandum of understanding to acquire Infusion Brands International, the marketer behind the renowned "Dual" brand and the strategic partner of Ronco Holdings.

December 19, 2013

Endo announced Thursday that regulatory waiting periods in the United States and Canada related to its plans to acquire a Montreal-based drug maker have been terminated.

MALVERN, Pa. — Endo announced Thursday that regulatory waiting periods in the United States and Canada related to its plans to acquire a Montreal-based drug maker have been terminated.

December 19, 2013

Meda has signed an agreement to acquire ZpearPoint AS, including global rights to its main product, EB24, an OTC line for treating dental erosion.

GÖTEBORG, Sweden — Meda has signed an agreement to acquire ZpearPoint AS, including global rights to its main product, EB24, an OTC line for  treating dental erosion.  

The EB24 product is based on hydrogen fluoride highly diluted in water. In studies, the product has shown that it is able to penetrate enamel surfaces and form calcium fluoride resulting in an anti-erosive effect. As such, EB24 works as a protective agent against dental erosion. 

December 18, 2013

Actelion has launched a topical gel used to treat a kind of skin cancer, the company said.

SOUTH SAN FRANCISCO, Calif. – Actelion has launched a topical gel used to treat a kind of skin cancer, the company said.

Actelion announced the launch of Valchlor (mechlorethamine), which the Food and Drug Administration approved in August for treating stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patient who have received skin-directed therapy before. Actelion acquired rights to the drug when it merged with Ceptaris Therapeutics. Accredo Specialty Pharmacy distributes the drug in the United States.

December 18, 2013

Mylan has acquired rights to an experimental respiratory drug made by Pfizer, Mylan said.

PITTSBURGH — Mylan has acquired rights to an experimental respiratory drug made by Pfizer, Mylan said Wednesday.

The drug maker said it had bought exclusive worldwide development, manufacturing and commercialization rights to the drug, which was not named, but was described as a long-acting muscarinic antagonist about to enter phase-2b, or mid-stage, clinical trials. Mylan said it would develop the drug into combination therapies and that they would use a multidose dry powder inhaler technology, also licensed from Pfizer.

December 16, 2013

Endo Health Solutions will acquire the maker of a patch used to treat migraines that received Food and Drug Administration approval at the beginning of this year.

MALVERN, Pa. – Endo Health Solutions will acquire the maker of a patch used to treat migraines that received Food and Drug Administration approval at the beginning of this year.

Endo said Monday that it would buy NuPathe for $105 million. In January, the FDA approved NuPathe's patch, Zecuity, a disposable, single-use, battery-powered transdermal patch that delivers the drug sumatriptan, the most widely prescribed migraine medication.

December 16, 2013

Everett Labs has acquired Quinnova Pharmaceuticals from Amneal Enterprises, Everett said Monday.

CHATHAM, N.J. — Everett Labs has acquired Quinnova Pharmaceuticals from Amneal Enterprises, Everett said Monday.

Everett Labs, a subsidiary of Spain-based Exeltis, said the purchase would help it expand into the U.S. dermatology and women's health markets. Financial terms of the deal were not disclosed.

December 16, 2013

Valeant Pharmaceuticals International will acquire Solta Medical for about $250 million, Valeant said Monday.

LAVAL, Quebec — Valeant Pharmaceuticals International will acquire Solta Medical for about $250 million, Valeant said Monday.

The Canadian drug maker said the $2.92-per-share acquisition represented a 40% premium over Solta's closing share price on Friday. Solta develops, manufactures and markets energy-based medical device systems for such cosmetic medical procedures as skin tightening, improving skin texture and others.

December 13, 2013

The Irish High Court has approved Perrigo's pending acquisition of Irish drug maker Elan, the companies said Friday.

ALLEGAN, Mich. — The Irish High Court has approved Perrigo's pending acquisition of Irish drug maker Elan, the companies said Friday.

December 13, 2013

Navarro Discount Pharmacy, which operates 33 locations in Southern Florida, has introduced a compliance packaging program, EZ Meds Medicine Packaging System, that organizes a patient’s prescription medications into individual packets with labels and instructions.

MIAMI, Fla. — Navarro Discount Pharmacy, which operates 33 locations in Southern Florida, has introduced a compliance packaging program, EZ Meds Medicine Packaging System, that organizes a patient’s prescription medications into individual packets with labels and instructions.

December 9, 2013

Covidien will acquire a company that markets a swallowed capsule used in medical imaging for $860 million, the hospital equipment manufacturer said Sunday.

DUBLIN — Covidien will acquire a company that markets a swallowed capsule used in medical imaging for $860 million, the hospital equipment manufacturer said Sunday.

Covidien announced a deal to acquire all outstanding shares of Given Imaging for $30 a share. Given Imaging specializes in products for visualizing, diagnosing and monitoring the digestive system, including its flagship product, PillCam.

December 4, 2013

Sears Holdings chairman and CEO Eddie Lampert has pared down his stake in the retailing company, according to a regulatory filing Tuesday.

NEW YORK — Sears Holdings chairman and CEO Eddie Lampert has pared down his stake in the retailing company, according to a regulatory filing Tuesday.

A Securities and Exchange Commission filing showed that Lampert reduced his stake in Sears Holdings to 48.4%, from a 55.4% stake reported in March. That leaves him with about 51.6 million shares in the company, whose stock was valued at $50.38 per share Wednesday morning on the NASDAQ, down from its opening price of $52.62.

December 3, 2013

Forest Labs is spending at least $240 million to buy rights to a psychiatric drug made by Merck, the New York-based drug maker said.

NEW YORK — Forest Labs is spending at least $240 million to buy rights to a psychiatric drug made by Merck, the New York-based drug maker said.

Forest said it would buy the U.S. rights for Merck's Saphris (asenapine), a tablet dissolved under the tongue for the treatment of schizophrenia and manic episodes in patients with bipolar disorder. Forest will pay Merck $240 million upfront, as well as milestone payments based on sales, while Merck will supply the drug. Forest will market the drug and conduct clinical studies.